EMMPRIN

EMMPRIN 詳細

英語名Basigin市販薬剤の数1
治験薬の数4ターゲットの別称BSG,Extracellular matrix metalloproteinase inducer,UNQ6505/PRO21383,Basigin (Ok Blood Group),Tumor Cell-Derived Collagenase Stimulatory Factor,Leukocyte Activation Antigen M6,Collagenase Stimulatory Factor,Basigin,5F7,Ok Blood Group,CD147 Antigen,EMPRIN,CD147,OK,TCSF,EMMPRIN,SLC7A11,OK blood group antigen
研究&開発段階Approved
英語名Basigin
ターゲットの別称BSG,Extracellular matrix metalloproteinase inducer,UNQ6505/PRO21383,Basigin (Ok Blood Group),Tumor Cell-Derived Collagenase Stimulatory Factor,Leukocyte Activation Antigen M6,Collagenase Stimulatory Factor,Basigin,5F7,Ok Blood Group,CD147 Antigen,EMPRIN,CD147,OK,TCSF,EMMPRIN,SLC7A11,OK blood group antigen
市販薬剤の数1
治験薬の数4
研究&開発段階Approved

EMMPRIN 製品リスト

  • 属性

    Protein (6)

  • 製品ライブラリ

    オンライン (6)

  • Human (4)Mouse (1)Cynomolgus (1)

  • タグ

    His Tag (3)Fc Tag (1)His Tag & Avi Tag (2)

  • マーカー

    Unconjugated (3)Biotin-labeled (2)FITC Labeled (1)

EMMPRINバックグランド

CD147, also known as Basigin (BSG), or extracellular matrix metalloproteinase inducer (EMMPRIN). The human basigin protein contains 269 amino acids that form two heavily glycosylated C2 type immunoglobulin-like domains at the N-terminal extracellular portion. A second form of basigin has also been characterized that contains one additional immunoglobulin-like domain in its extracellular portion. As members of the immunoglobulin superfamily play fundamental roles in intercellular recognition involved in various immunologic phenomena, differentiation, and development, basigin is thought also to play a role in intercellular recognition and regulate several distinct functions, such as spermatogenesis, expression of the monocarboxylate transporter and the responsiveness of lymphocytes. Basigin is a type I integral membrane receptor that has many ligands, including the cyclophilin (CyP) proteins Cyp-A and CyP-B and certain integrins.

EMMPRIN分子の別称

Basigin,BSG,5F7,CD147,EMMPRIN,M6,OK,TCSF

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
MertuzumabPhase 3 ClinicalInstitute Of Medicine Fourth Military Medical University, Jiangsu Pacific Minok Biopharmaceutical Co., Ltd.Carcinoma, Non-Small-Cell Lung; Coronavirus Disease 2019 (COVID-19)
詳細
MeplazumabHI6H8Phase 3 ClinicalInstitute Of Medicine Fourth Military Medical University, Jiangsu Pacific Minok Biopharmaceutical Co., Ltd.Coronavirus Disease 2019 (COVID-19); Malaria; Malaria, Falciparum; Post-Acute COVID-19 Syndrome
詳細
humanized ADCC cHAb18 antibody (Pacific Meinuoke/Fourth Military Medical University)Phase 1 ClinicalAir Force Medical UniversityCarcinoma, Non-Small-Cell Lung
詳細
CD147-CAR T cell therapy (Peking University People's Hospital)Phase 1 ClinicalPeking University People'S HospitalLymphoma, T-Cell
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
Iodine[131I] MetuximabApprovedChengdu Huasun Biotechnology Co LtdLicartin, 利卡汀Mainland ChinaCarcinoma, HepatocellularChengdu Huasun Biotechnology Co Ltd2006-10-12Carcinoma, Hepatocellular
詳細
  • 詳細
  • 製品リスト
  • 市販薬剤に関する情報
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8